Headquartered in Arlington, MA Fiscal year ends December NASDAQ: KALA kalarx.com
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of therapies using its proprietary nanoparticle-based mucus penetrating particle (MPP) technology for the treatment of eye diseases. The company is headquartered in Watertown, Massachusetts.
Always be cautious before investing in a penny stock. While some will turn out to be explosive winners, like Advanced Micro Devices, others turn out to be expensive duds. That’s because some…
Friday's top analyst upgrades and downgrades included AMC Entertainment, CNH Industrial, Kala Pharmaceuticals, Opendoor Technologies, Tesla and TG Therapeutics.
Kala Pharmaceuticals said that it had positive topline results from its late-stage clinical trial for the treatment of dry eye disease.
Chris Lange Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of therapies using its proprietary nanoparticle-based mucus penetrating particle (MPP) technology for the treatment of eye diseases. The company is headquartered in Watertown, Massachusetts.
The Wall Street consensus 12-month price target for KALA is $1.50.
